We sit down with Lumen Biosciences CEO Brian Finrow to discuss how his company hopes to use its spirulina-based platform to develop drugs targeting gastrointestinal disorders.
Lumen Biosciences is a biotech looking to unlock the full potential of biologic drugs, whose promise has been held back by the lack of scalable technology.
The firm is developing ‘oral antibodies’ using its platform based on spirulina– the protein-rich cyanobacteria touted by many health enthusiasts as a ‘superfood’ – to create tiny factories that churn out therapeutic antibodies.
Image: Stock Photo Secrets
More details can be found in the text box below, but as part of the BioProcess International Theater at BIO in San Diego last month, I spoke with CEO and co-founder Brian Finrow.
Listen to the full interview as part of the Bioprocess Insider Expression Platform podcast here, on Apple, Amazon, Spotify, or wherever you get your podcasts.
You May Also Like
schedl_b_and_w.jpg?width=100&auto=webp&quality=80&disable=upscale "Picture of Dan Stanton")
schedl_b_and_w.jpg?width=400&auto=webp&quality=80&disable=upscale "Dan Stanton")
